Ajinomoto to buy gene therapy CDMO Forge Biologics in $620M all-cash deal

CD­MO and biotech Forge Bi­o­log­ics will be ac­quired by Aji­nomo­to in an all-cash deal worth $620 mil­lion, a move that will see the Japan-based multi­na­tion­al con­glom­er­ate en­ter the gene ther­a­py man­u­fac­tur­ing space.

“Clear­ly, Aji­nomo­to is see­ing this as a bet on the fu­ture of gene ther­a­py, and that this will be­come a more im­por­tant part of CD­MO of­fer­ings in­to the fu­ture,” Forge board chair Chris Garabe­di­an told End­points News in an in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.